The FY23 Defense Appropriations Act is anticipated to provide funding for the TSCRP to support innovative, high-impact tuberous sclerosis complex (TSC) research. The managing agent for the anticipated funding opportunities is the CDMRP at the US Army Medical Research and Development Command (USAMRDC).
The TSCRP is providing information in a pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities. The FY23 TSCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY23 TSCRP must address one or more of the following Focus Areas:
- Understanding, preventing, and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological, behavioral, and surgical interventions
- Strategies for eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of tumor microenvironment, TSC signaling and mTOR-independent pathways
- Preventing, epilepsy, improving treatment, and mitigating neurodevelopmental and adverse outcomes associated with TSC-related seizures
- Developing, assessing, and testing emerging technologies including imaging and molecular therapeutic strategies, such as gene therapy, to improve outcomes in TSC
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).